BioTimeâs Subsidiary Cell Cure Neurosciences Receives FDA Authorization to Initiate Phase I/IIa Trial of Embryonic Stem Cell-Derived OpRegenÂ® for the Treatment of the Dry Form of Age-Related Macular Degeneration